Majority of the present GLP-1 based studies employ GLP-1 analogs such as exenatide as their primary drugs, which raises a question for their cardiovascular safety and contribution to major adverse cardiovascular events (MACE)
Despite this, Novo Nordisk has been heavily advertising this medication, claiming it can help individuals lose weight and keep it off
[DOI] [PMC free article] [PubMed] [Google Scholar] 804
If weight management is your goal, some IV formulations can assist with fat burning
MIA injection significantly reduced the withdrawal threshold of the ipsilateral paw compared with the saline group until the end of the study
By mimicking natural GLP-1 activity in the brain, semaglutide slows digestion, reduces hunger, and decreases glucagon secretion